CAR T-Cell Therapy Market Analysis

The CAR T-cell therapy market is segmented by indication, by target antigen and by region. On the basis of indication, the market is further segmented into acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL) and others, out of which, the DLBCL segment is anticipated to hold the largest share in the market on account of growing cases of the condition which raise the demand for CAR T-cell therapy. The segment for multiple myeloma is another segment anticipated to observe significant growth in the market as a result of rising research and development in that area. Based on target antigen, the market is segmented into CD19, CD20, CD22, CD30, GD2 and others. Out of these, the segments for CD19 and CD20 target antigens are anticipated to hold the largest shares in the CAR T-cell therapy market. This can be attributed to the high approval rate of therapies containing these antigens.

Our in-depth analysis of the global market includes the following segments:

By Indication	Acute Lymphoblastic Leukemia [ALL] Chronic Lymphocytic Leukemia [CLL] Multiple Myeloma [MM] Diffuse Large B Cell Lymphoma [DLBCL] Others
By Target Antigen	CD19 CD20 CD22 CD30 GD2 Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of CAR T-cell therapy is estimated at USD 7.28 billion.

CAR T-Cell Therapy Market size was valued at USD 5.9 billion in 2024 and is likely to cross USD 140.25 billion by 2037, registering more than 27.6% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, attributed to growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA).

The major players in the market are Novartis International AG, Gilead Sciences, Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Sorrento Therapeutics, Celgene Corporation and Bluebird Bio.

CAR T-Cell Therapy Market Analysis